KPV

Typical use cases

Dosing guidelines

Titration

No validated titration schedule exists. Community protocols sometimes describe starting at a lower dose and observing tolerance before adjusting; this is reported informally and is not clinically established.

Reconstitution

For injectable use, lyophilized powder is typically reconstituted with bacteriostatic water added slowly down the vial wall and swirled (not shaken) until clear; e.g., adding 2 mL to a 10 mg vial yields 5 mg/mL (5000 mcg/mL). Oral capsule and topical/cream formulations do not require reconstitution.

Injection sites

Route varies by formulation: subcutaneous injection (commonly abdomen or other subcutaneous fat areas) for injectable powder; also used orally (capsule) and topically on skin. Reconstitution/injection not applicable for the oral and topical forms.

Storage & handling

Store lyophilized powder frozen (around -20 C) and protected from light; once reconstituted, refrigerate at 2-8 C and use within roughly 2-4 weeks. Avoid repeated freeze-thaw cycles.

Side effects

• Injection-site reaction (redness, irritation, mild discomfort) Mild · Common
• Transient skin irritation or redness with topical use Mild · Uncommon
• Gastrointestinal upset (more often noted at higher oral doses) Mild · Uncommon
• Headache or fatigue (anecdotally reported) Mild · Rare
• Allergic/hypersensitivity reaction Moderate · Rare

Research summary

KPV is the C-terminal Lys-Pro-Val fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), and preclinical work shows it retains much of the parent hormone's anti-inflammatory activity while largely shedding its pigmentary and melanocortin-receptor effects. The most cited mechanistic study (Dalmasso et al., Gastroenterology 2008) demonstrated that KPV is taken up into intestinal epithelial and immune cells via the di/tripeptide transporter PepT1, where at nanomolar concentrations it inhibits NF-kB and MAP-kinase signaling and reduces secretion of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta); orally administered KPV reduced disease severity in both DSS- and TNBS-induced mouse colitis models. Later work (Xiao et al., Molecular Therapy 2017) showed hyaluronic-acid-functionalized nanoparticles can target KPV to inflamed colon tissue, accelerating mucosal healing and lowering TNF-alpha in murine ulcerative colitis. Additional preclinical and in-vitro studies report activity in models of bronchial/airway inflammation (KPV suppressing NF-kB, IL-8 and MMP-9 in human bronchial epithelial cells, in part via MC3R), contact dermatitis, and keratinocyte protection, and transdermal-delivery research (e.g., iontophoresis across microporated skin) has explored topical routes. The overall evidence base is almost entirely preclinical (cell culture and rodent models); there are no large, published, peer-reviewed randomized controlled trials establishing efficacy, dosing, or long-term safety in humans. KPV is not approved by the FDA or EMA and is generally sold only as a research chemical, so human pharmacokinetics, optimal dosing, and safety remain poorly characterized. Reported tolerability in available sources is favorable with mostly mild, localized effects, but this reflects limited and largely uncontrolled observation rather than rigorous clinical data.

Key references

• https://pubmed.ncbi.nlm.nih.gov/18061177/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/
• https://en.wikipedia.org/wiki/KPV_tripeptide

Related compounds